
Incyte Wins FDA Approval for Jakafi XR™ Extended-Release Tablets Across Multiple Hematologic Indications
Incyte Secures FDA Approval for Jakafi XR™ (ruxolitinib) Extended-Release Tablets Across Multiple Hematologic Indications Incyte has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets, introducing a new once-daily treatment option for patients…












